Venus Remedies Ltd

₹ 1,798 4.80%

12 Jun - close price

venusremedies.com BSE: 526953 NSE: VENUSREM

About

Incorporated in 1989, Venus Remedies
Ltd is a research based pharmaceutical company and an injectable manufacturer^[1]

Key Points

Business Overview:^[1]^[2]
VSR is one of the largest manufacturers of meropenem antibiotics and emerging player in AMR drug in India. It offers a wide range of pharmaceutical products that cater to various therapeutic areas, including anti infective (antibiotics), antimicrobial resistance, oncology, neurology, pain management, skin
& wound care. Company has 1040+ marketing authorizations globally, 135+ patents and 180+ product basket which includes formulations such as injectables,
tablets, and topical preparations

Website BSE NSE

Market Cap ₹ 2,401 Cr.
Current Price ₹ 1,798
High / Low ₹ 1,802 / 416
Stock P/E 23.4
Book Value ₹ 497
Dividend Yield 0.00 %
ROCE 21.7 %
ROE 16.8 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company is almost debt free.
Company has delivered good profit growth of 21.8% CAGR over last 5 years

Cons

Stock is trading at 3.62 times its book value
The company has delivered a poor sales growth of 7.18% over past five years.
Company has a low return on equity of 10.5% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	156	95	168	143	195	109	170	177	195	137	193	180	259
	131	85	150	131	176	97	163	158	166	122	162	143	196
Operating Profit	25	10	18	12	19	11	8	18	29	15	31	38	63
OPM %	16%	11%	11%	8%	10%	10%	4%	10%	15%	11%	16%	21%	24%
	3	2	3	2	4	2	8	12	7	3	2	3	5
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	8	8	6	7	6	6	6	5	5	6	6	7	7
Profit before tax	20	5	14	8	17	7	9	25	31	13	26	33	62
Tax %	44%	77%	31%	12%	40%	82%	61%	21%	32%	24%	24%	24%	23%
	11	1	10	7	11	1	4	20	21	10	20	26	48
EPS in Rs	8.27	0.88	7.44	5.12	7.86	0.91	2.63	14.66	15.71	7.18	15.06	19.14	35.54
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	455	407	400	372	322	335	544	597	552	596	640	770
	366	326	349	333	289	295	490	535	492	537	577	622
Operating Profit	89	81	51	39	33	41	54	62	60	60	64	147
OPM %	20%	20%	13%	11%	10%	12%	10%	10%	11%	10%	10%	19%
	1	2	2	2	-3	-4	43	8	10	12	31	13
Interest	41	38	34	35	25	13	13	0	0	0	0	0
Depreciation	46	42	40	34	34	32	35	34	32	26	23	26
Profit before tax	3	4	-22	-28	-30	-8	49	36	38	45	72	134
Tax %	-95%	52%	-21%	11%	-4%	24%	-27%	-12%	30%	36%	37%	23%
	5	2	-17	-31	-29	-10	62	41	27	28	45	103
EPS in Rs	4.51	1.49	-13.84	-24.87	-23.15	-8.10	50.05	30.46	19.88	21.31	33.90	76.90
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	13%

Compounded Sales Growth
10 Years:	7%
5 Years:	7%
3 Years:	12%
TTM:	20%

Compounded Profit Growth
10 Years:	51%
5 Years:	22%
3 Years:	57%
TTM:	174%

Stock Price CAGR
10 Years:	36%
5 Years:	42%
3 Years:	98%
1 Year:	303%

Return on Equity
10 Years:	5%
5 Years:	10%
3 Years:	10%
Last Year:	17%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	11	11	12	12	12	12	12	13	13	13	13	13
Reserves	445	426	376	350	320	311	388	427	447	474	548	650
	321	335	312	307	298	220	51	43	42	41	2	12
	64	70	65	82	102	100	104	97	98	98	153	178
Total Liabilities	841	843	765	751	733	644	556	580	601	627	716	854
	444	452	406	389	364	289	262	241	216	219	229	232
CWIP	78	80	66	65	65	25	25	25	26	21	26	51
Investments	0	0	0	0	0	0	0	0	20	19	84	238
	319	310	293	297	304	330	269	314	339	368	376	333
Total Assets	841	843	765	751	733	644	556	580	601	627	716	854

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	68	47	59	31	45	78	132	41	37	37	86	156
	-67	3	-18	8	-11	-5	57	-17	-58	-8	-77	-182
	-1	-46	-44	-39	-35	-73	-162	-9	-1	-1	-1	-3
Net Cash Flow	-1	3	-4	0	-1	-0	27	14	-22	28	9	-29
Free Cash Flow	59	46	41	19	35	70	132	41	29	24	69	118
CFO/OP	76%	58%	116%	79%	139%	190%	245%	66%	61%	89%	160%	129%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	51	55	43	46	43	33	21	24	51	49	64	49
Inventory Days	194	219	226	246	286	296	129	118	132	125	97	122
Days Payable	40	38	48	52	72	77	76	47	56	55	89	107
Cash Conversion Cycle	204	236	221	240	257	252	74	95	127	120	72	64
Working Capital Days	54	69	54	25	-1	73	71	82	109	118	86	97
ROCE %	6%	5%	2%	1%	1%	2%	8%	8%	8%	9%	11%	22%

Insights

In beta

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Global Presence (Countries)
Number

xx	xx	xx	xx	xx	xx	xx	xx	xx	xx
x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx		x,xxx	xxx	xx,xxx
xxx	xxx	xxx	xxx		xxx	xxx	xxx	x,xxx	x,xxx
xxx	x,xxx	x,xxx	x,xxx	x,xxx			x,xxx	xx,xxx	xx,xxx
xxx	xxx		xxx		xxx	xxx	xxx	xxx	xxx
xxx.xx	xxx.xx	xxx.xx					xxx.xx	xx.xx	xxx.xx
	xx	xx		xx		xxx		xxx	xxx
							x	x	x
xx.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx

Please log in to see hidden values.

Stockist Network
Number ・Standalone data

Total Marketing Authorizations (Cumulative)
Number

Hospital Reach
Number ・Standalone data

Patents Granted (Cumulative)
Number

Annual Manufacturing Capacity (Injectables)
Million Units

New Product Approvals (Annual)
Number

Internal Product Rejections
Number ・Standalone data

R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%
	0.98%	1.03%	1.59%	1.48%	1.06%	1.18%	1.11%	1.34%	2.25%	1.86%	2.25%	2.80%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.11%	0.75%	1.03%	1.20%
	57.26%	57.21%	56.65%	56.76%	57.17%	57.06%	57.13%	56.90%	55.89%	55.62%	54.95%	54.24%
No. of Shareholders	20,498	19,267	19,560	19,913	19,614	19,557	19,771	19,982	19,307	17,725	18,606	18,403

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	37.51%	37.51%	37.51%	35.89%	35.89%	40.81%	41.76%	41.76%	41.76%	41.76%
	0.48%	0.48%	0.04%	0.04%	0.04%	0.33%	1.00%	1.48%	1.34%	2.80%
	0.28%	0.45%	0.02%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.20%
	61.73%	61.56%	62.43%	64.07%	64.07%	58.86%	57.26%	56.76%	56.90%	54.24%
No. of Shareholders	20,556	19,316	18,375	17,209	13,829	19,952	21,719	19,913	19,982	18,403

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Venus Remedies Ltd

Venus Remedies Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Insights

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings